National
Log Cabin says Boehner helpful on ‘Don’t Ask’ vote
GOP election victories shine spotlight on gay Republican group
Rep. John Boehner (R-Ohio), who is expected to become Speaker of the House in January, agreed to a request by the gay GOP group Log Cabin Republicans not to penalize House Republicans who voted in May for repeal of “Don’t Ask, Don’t Tell,” according to the group’s leader.
Log Cabin Executive Director R. Clarke Cooper said Boehner agreed to his request that the House minority leader not order a Republican whip count for an amendment to a defense authorization bill calling for repealing “Don’t Ask, Don’t Tell.” Whip counts are sometimes viewed as a means of pressuring members to vote the way party leaders want them to vote, and House GOP leaders, including Boehner, opposed the repeal amendment.
In what he called a conciliatory gesture, Cooper said Boehner agreed to his request to “no whip” the amendment during a conversation at a political event days before the House voted 234 to 194 on May 27 to approve it. Only five Republicans voted for the amendment, which was introduced by Rep. Patrick Murphy (D-Pa.).
“He did not do a whip count,” Cooper said. “And in the grand scheme of things it’s not the biggest deal on the planet. But I saw it as a positive indicator that he didn’t blow me off.”
The repeal measure died in a Senate filibuster. Senate Democratic leaders have promised to bring it up again later this month in a congressional “lame duck” session, but its prospects for passing are uncertain.
Meanwhile, with Republicans winning control of the House in Tuesday’s midterm elections, LGBT activists and Capitol Hill pundits will likely weigh Cooper’s interaction with Boehner as part of their assessment of whether gay Republicans will have access to and influence with House GOP leaders over pending LGBT legislation.
Although Democrats retained their control of the Senate, most political observers — including LGBT advocates — agree that major LGBT-related bills would have no chance of passing in Congress next year without the consent of Republican leaders like Boehner. And most observers believe House Republicans won’t allow gay bills to come to the House floor for a vote.
Cooper, however, said he and his Log Cabin team have a plan for persuading congressional Republican leaders to consider and agree to a vote on at least two gay bills. According to Cooper, one is an as yet to be unveiled tax reform bill that would address “tax inequities that affect the gay community.” The other is the Employment Non-Discrimination Act, or ENDA, which Democratic leaders declined to bring up for a vote during the past two years. The measure calls for banning employment discrimination based on sexual orientation and gender identity.
Cooper said the tax bill would appeal to “the broader conservative community” while addressing inequities in the gay community.
“We would be attracting new or additional allies that we’ve not had in the past,” he said. “There are several members of Congress right now who don’t have a record, good or bad, or who are unknown to our community. And this gives them an opportunity to put a toe in the water on doing pro-equality measures.”
Cooper said the tax bill, the details of which would be released at the start of the new Congress in January, would help pave the way for more Republican support for ENDA.
Other LGBT organizations issued statements Tuesday night saying the Republican takeover of the House and the increased number of Republicans elected to the Senate would essentially eliminate any chance of passing LGBT bills for at least two years.
National Stonewall Democrats, the Human Rights Campaign and the National Gay & Lesbian Task Force each released statements describing the new crop of Republican leaders as “anti-equality.”
HRC noted that Boehner; Rep. Eric Cantor (R-Va.), the expected new House majority leader; and Rep. Mike Pence (R-Ind.), the expected majority whip, each received an HRC scorecard rating of “0” on LGBT issues over the past two years.
D.C. Council member David Catania (I-At-Large), who won election to another term on Tuesday, said his opinion of the Republican Party as an impediment to LGBT equality hasn’t changed since he left the party in 2004 over its support for a constitutional amendment to ban same-sex marriage.
“If the question is what impact gay Republicans will have in a Republican-controlled Congress, the answer is none,” Catania said. “And if the last 10 years has demonstrated anything it’s that the Republican Party has no interest in a big tent, no interest in having gay Republicans at the table.”
“And the fact that gay Republicans continue to live in a fantasy land as if they mattered to the establishment in the GOP is mind blowing,” he said.
A spokesperson for House Speaker Nancy Pelosi (D-Calif.), who will be replaced as speaker by Boehner in January, gave an equally harsh assessment of the influence of gay Republicans under the new Congress.
“They have got to be drinking some serious Kool-Aid over at Log Cabin Republicans’ headquarters,” said Pelosi spokesperson Drew Hammill. “To think that a Republican majority would do anything to advance equality for the LGBT community is simply delusional.”
Mara Keisling, executive director of the National Center for Transgender Equality, which has been among the lead groups lobbying for ENDA, said she hopes Log Cabin does have access and influence over congressional GOP leaders.
But she noted that some of Log Cabin’s effort could be undercut by what appears to be a rival gay Republican group, GOProud.
Founded by conservative gay GOP activist Christopher Barron, who broke away from Log Cabin two years ago, GOProud received criticism from LGBT activists this fall for producing a campaign ad calling for the defeat of gay Rep. Barney Frank (D-Mass.). The ad accused Frank of being responsible for “the financial meltdown that devastated our economy” in his role as chair of the House committee that approved government bailouts for banks.
Other activists note that Log Cabin had its own financial meltdown in 2008, when money problems resulted in the layoff of its entire Washington staff. The group’s board and state and local chapters remained active and kept the group going until funds were raised to hire a new executive director and a small Washington staff.
Cooper and other Log Cabin supporters strongly dispute claims that congressional GOP leaders will ignore the group. They note that unlike the last GOP takeover of Congress, virtually none of the current crop of Republican candidates ran on an anti-gay or anti-same-sex marriage platform. Economic issues and the Tea Party-led revolt this year against “big government” overshadowed social issues like gay marriage, Cooper and other Log Cabin members said.
Richard Tafel, who served as Log Cabin’s executive director in the 1990s, told the Blade Tuesday that he believes the new GOP-controlled House will be far more receptive to LGBT equality issues than the GOP Congress he contended with nearly a decade ago.
“I think the Republicans have learned a very harsh lesson from the ‘90s, when I was there, which is gay bashing didn’t work. It was fundamentally a flaw … the Tea Party is all about fiscal responsibility,” he said, adding that the new GOP leadership will likely follow that path rather than expend resources opposing gay equality issues.
Gay Republican activist Jim Driscoll, who served on the Presidential Advisory Council on HIV/AIDS during the Bush administration, said Log Cabin’s influence “will be heavily dependent” on its willingness to support Republicans on non-LGBT issues like the economy and GOP positions on AIDS programs.
“Regardless of how Log Cabin fares, I believe that most Republican offices will be more receptive to openly gay Republicans than any time before,” Driscoll said. “Republicans will realize that this election was not won on social issues or gay baiting. In fact, nearly all Republican strategists and consultants advised their candidates to keep quiet or tone down on this one.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Protecting the trans community is not optional for elected allies and candidates
Trump’s ‘American people derangement syndrome’
